Trial Profile
An open-label, single dose clinical study to evaluate the safety, tolerance and immunogenicity of Fluviral trivalent split virion influenza vaccine (2006 -2007 season) in adults aged between 18 and 60 and over 60
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 1536489A (Primary) ; Influenza virus vaccines
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 03 Jul 2007 New trial record.